Home › Multiple Myeloma › NCT07333261

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

A Phase 1b Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Newly Diagnosed Multiple Myeloma

Who can join

Ages 19 and older · All sexes

Inclusion Criteria:

1. Age \> 18 years with no upper age limit
2. NDMM with indication for initiation of therapy diagnosed within last 12 months. Pretreatment parameters necessary for disease characterization and response assessment must be available.
3. Not eligible for ASCT by institutional criteria or deferring ASCT due to personal preference.
4. ECOG performance status 0-1
5. Adequate organ function

Exclusion Criteria:

1. Known active or history of central nervous system (CNS) involvement of MM.
2. Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS or clinically significant amiloidosis.
3. Prior history of other malignancies
4. Uncontrolled infection

Other protocol-defined Inclusion/Exclusion criteria apply.

About the study

This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.

What is being tested

• BMS-986453 (drug)

Sponsor: Susan Bal · Participants: 25 · Started: Feb 9, 2026

Contact the study team

• Susan Bal, MD · Phone: (205) 934-7645

Official record on ClinicalTrials.gov — NCT07333261

Locations in the U.S.

Conditions

• Multiple Myeloma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.